Loading...
•
Sep 30, 2024
Mersana Q3 2024 Earnings Report
Mersana reported its Q3 2024 financial results and provided a business update.
Key Takeaways
Mersana Therapeutics reported its Q3 2024 financial results, highlighting the advancement of XMT-1660 and XMT-2056 clinical trials, progress in collaborations, and maintenance of a strong balance sheet. The company is preparing to present initial XMT-1660 clinical data and initiate the expansion portion of its trial.
Advanced the dose escalation portions of Phase 1 clinical trials of XMT-1660 and XMT-2056.
Made further progress in collaborations with Johnson & Johnson and Merck KGaA, Darmstadt, Germany.
Preparing to present initial XMT-1660 clinical data later this year and initiate the expansion portion of the trial in patients with TNBC.
Achieved an $8 million development milestone under the Johnson & Johnson collaboration and a $1 million development milestone under the Merck KGaA, Darmstadt, Germany collaboration.
Revenue by Segment
Forward Guidance
Mersana plans to share initial safety, tolerability, efficacy and biomarker data from its Phase 1 dose escalation and backfill cohorts at a company event and to initiate the expansion portion of the trial in patients with TNBC who have previously been treated with at least one topo-1 ADC.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...